Intercept Pharmaceuticals (ICPT) Downgraded by Royal Bank of Canada

Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by equities researchers at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Wednesday, The Fly reports. The analysts noted that the move was a valuation call.

Other equities research analysts also recently issued reports about the company. Wedbush restated a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Friday, May 18th. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 7th. Cantor Fitzgerald restated a “hold” rating and issued a $58.00 target price on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 8th. Oppenheimer set a $100.00 target price on Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, August 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $117.67.

ICPT opened at $111.65 on Wednesday. The company has a market capitalization of $3.36 billion, a price-to-earnings ratio of -7.76 and a beta of -1.68. The company has a debt-to-equity ratio of 2.48, a current ratio of 6.51 and a quick ratio of 6.51. Intercept Pharmaceuticals has a 1-year low of $51.05 and a 1-year high of $121.92.



Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.83) by $0.25. The firm had revenue of $43.58 million during the quarter, compared to the consensus estimate of $41.26 million. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The firm’s revenue for the quarter was up 41.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($3.46) earnings per share. analysts predict that Intercept Pharmaceuticals will post -10.86 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. US Bancorp DE lifted its position in shares of Intercept Pharmaceuticals by 821.6% during the 1st quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 1,561 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $252,000. Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $264,000. United Services Automobile Association acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $280,000. Finally, Xact Kapitalforvaltning AB acquired a new stake in shares of Intercept Pharmaceuticals during the 2nd quarter valued at $282,000. Institutional investors own 66.63% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Article: Understanding Analyst Recommendations

The Fly

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply